

## DAFTAR PUSTAKA

- (Agust, 2020; Bailey, 2012; MacNee, 2005; Soeroto, n.d.) Agust, A. G. N. (2020). Forced Expiratory Volume. In *Definitions*. Qeios.  
<https://doi.org/10.32388/i7tpmz>
- Antunes, M., Lapa e Silva, J. R. and Rocco, P. (2017) ‘Mesenchymal stromal cell therapy in COPD: from bench to bedside’, *International Journal of Chronic Obstructive Pulmonary Disease*. Dove Medical Press Ltd., Volume 12, pp. 3017–3027. doi: 10.2147/COPD.S146671.
- Antunes MA, Lapa e Silva JR, R. P. (2017) *Mesenchymal stromal cell therapy in COPD: from bench to bedside*, Dovepress. Available at: <https://www.dovepress.com/mesenchymal-stromal-cell-therapy-in-copd-from-bench-to-bedside-peer-reviewed-fulltext-article-COPD> (Accessed: 9 July 2020).
- Bailey, K. L. (2012). The importance of the assessment of pulmonary function in COPD. In *Medical Clinics of North America* (Vol. 96, Issue 4, pp. 745–752). NIH Public Access. <https://doi.org/10.1016/j.mcna.2012.04.011>
- Basics About COPD - Chronic Obstructive Pulmonary Disease (COPD)* (2019) Centers for Disease Control and Prevention. Available at: <https://www.cdc.gov/copd/basics-about.html> (Accessed: 9 July 2020).
- Broekman, W. *et al.* (2018a) ‘Mesenchymal stromal cells: A novel therapy for the treatment of chronic obstructive pulmonary disease?’, *Thorax*. BMJ Publishing Group, pp. 565–574. doi: 10.1136/thoraxjnl-2017-210672.
- Broekman, W. *et al.* (2018b) *Mesenchymal stromal cells: a novel therapy for the treatment of chronic obstructive pulmonary disease? | Thorax*, *Thorax*. Available at: <https://thorax.bmj.com/content/73/6/565.full> (Accessed: 6 October 2020).
- Cheng, S. L., Lin, C. H. and Yao, C. L. (2017a) *Mesenchymal Stem Cell Administration in Patients with Chronic Obstructive Pulmonary Disease: State of the Science*, *Stem Cells International*. Available at: <https://www.hindawi.com/journals/sci/2017/8916570/> (Accessed: 5 October 2020).
- Cheng, S. L., Lin, C. H. and Yao, C. L. (2017b) ‘Mesenchymal Stem Cell Administration in Patients with Chronic Obstructive Pulmonary Disease: State of the Science’, *Stem Cells International*. Hindawi Limited, 2017. doi: 10.1155/2017/8916570.
- Muhammad Bariq Rifqi Pasha, 2021  
**EFIKASI TERAPI BONE MARROW MESENCHYMAL STEM CELLS (BM-MSCS) PADA PASIEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)**  
UPN Veteran Jakarta, Fakultas Kedokteran, Program Studi Kedokteran Program Sarjana  
[[www.upnvj.ac.id](http://www.upnvj.ac.id) – [www.library.upnvj.ac.id](http://www.library.upnvj.ac.id) – [www.repository.upnvj.ac.id](http://www.repository.upnvj.ac.id)]

*Chronic Obstructive Pulmonary Disease (COPD)* (2018) *Centers for Disease Control and Prevention*. Available at: <https://www.cdc.gov/copd/index.html> (Accessed: 9 July 2020).

*Cochrane PICO search* (2020) *Cochrane Library*. Available at: <https://www.cochranelibrary.com/about/pico-search> (Accessed: 22 June 2020).

Coffta, M. (2020) *Literature Review, Bloomsburg Univeristy*. Available at: <https://guides.library.bloomu.edu/litreview> (Accessed: 22 June 2020).

Cona, L. A. (2020) *What are Mesenchymal Stem Cells (MSCs)?, DVC Stem*. Available at: <https://www.dvcstem.com/post/what-are-mesenchymal-stem-cells> (Accessed: 9 July 2020).

*COPD* (2019) *National Heart, Lung, and Blood Institute*. Available at: <https://www.nhlbi.nih.gov/health-topics/copd> (Accessed: 9 July 2020).

*COPD 1: pathophysiology, diagnosis and prognosis* (2020) *Nursing Times*. Available at: <https://www.nursingtimes.net/clinical-archive/respiratory-clinical-archive/copd-1-pathophysiology-diagnosis-and-prognosis-23-03-2020/> (Accessed: 9 July 2020).

*Data extraction forms* (2020) *Cochrane Developmental, Psychosocial and Learning Problems*. Available at: <https://dplp.cochrane.org/data-extraction-forms> (Accessed: 22 June 2020).

*Diagnosis of COPD* (no date) *WHO*. Available at: <https://www.who.int/respiratory/copd/diagnosis/en/> (Accessed: 9 July 2020).

Downs, S. H. and Black, N. (1998a) *The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions*, *J Epidemiol Community Health*. Available at: <https://jech.bmj.com/content/jech/52/6/377.full.pdf> (Accessed: 20 October 2020).

Downs, S. H. and Black, N. (1998b) 'The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions', *J Epidemiol Community Health*, 52, pp. 377–384. doi: 10.1136/jech.52.6.377.

*Ghrelin | You and Your Hormones from the Society for Endocrinology* (2018) *You and your Hormones*. Available at: <https://www.yourhormones.info/hormones/ghrelin/> (Accessed: 9 October 2020).

**Muhammad Bariq Rifqi Pasha, 2021**  
**EFIKASI TERAPI BONE MARROW MESENCHYMAL STEM**  
**CELLS (BM-MSCS) PADA PASIEN CHRONIC OBSTRUCTIVE**  
**PULMONARY DISEASE (COPD)**

UPN Veteran Jakarta, Fakultas Kedokteran, Program Studi Kedokteran Program Sarjana  
[www.upnvj.ac.id](http://www.upnvj.ac.id) – [www.library.upnvj.ac.id](http://www.library.upnvj.ac.id) – [www.repository.upnvj.ac.id](http://www.repository.upnvj.ac.id)

- Hemmingway, P. N. B. (2009) 'What is a systematic review?', *Hayward Medical Communications*. Available at: [www.whatisseries.co.uk](http://www.whatisseries.co.uk) (Accessed: 22 June 2020).
- Higgins, J. P. T. *et al.* (2011a) 'The Cochrane Collaboration's tool for assessing risk of bias in randomised trials', *BMJ*. British Medical Journal Publishing Group, 343(7829). doi: 10.1136/bmj.d5928.
- Higgins, J. P. T. *et al.* (2011b) *The Cochrane Collaboration's tool for assessing risk of bias in randomised trials | The BMJ, BMJ*. Available at: <https://www.bmj.com/content/343/bmj.d5928> (Accessed: 20 October 2020).
- Ho, T. *et al.* (2019) 'Under-and over-diagnosis of COPD: A global perspective', *Breathe*. European Respiratory Society, 15(1), pp. 24–35. doi: 10.1183/20734735.0346-2018.
- Iwakura, H. *et al.* (2017a) *The effects of inflammatory cytokines on the expression of ghrelin, Endocrine Journal*. Available at: [https://www.jstage.jst.go.jp/article/endocrj/64/Suppl./64\\_64.S25/\\_article](https://www.jstage.jst.go.jp/article/endocrj/64/Suppl./64_64.S25/_article) (Accessed: 9 October 2020).
- Iwakura, H. *et al.* (2017b) 'The effects of inflammatory cytokines on the expression of ghrelin', *Endocrine Journal*. Japan Endocrine Society, 64(Suppl.), pp. S25–S26. doi: 10.1507/endocrj.64.S25.
- John Wiley & Sons, I. (2020) *EBM: Levels of Evidence - Essential Evidence Plus, Essential Evidence Plus*. Available at: [https://www.essentialevidenceplus.com/product/ebm\\_loe.cfm?show=oxford](https://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford) (Accessed: 19 October 2020).
- Journal Impact Factor (IF) - Measuring Your Impact: Impact Factor, Citation Analysis, and other Metrics - Subject and Course Guides at University of Illinois at Chicago* (no date). Available at: <https://researchguides.uic.edu/if/impact> (Accessed: 4 July 2020).
- Khrisna (2017) *Data Primer dan Sekunder, Data riset*. Available at: <http://datariset.com/olahdata/detail/data-primer-dan-sekunder> (Accessed: 22 June 2020).
- Kokturk, N. *et al.* (2018) 'Stem cell therapy in chronic obstructive pulmonary disease. How far is it to the clinic?', *American journal of stem cells*. e-Century Publishing Corporation, 7(3), pp. 56–71. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/30245915> (Accessed: 9 July 2020).
- Levels of Evidence - Evidence-Based Practice for Health Professionals* (2020) *Northern Virginia Community College*. Available at: <https://libguides.nvcc.edu/c.php?g=361218&p=2439383> (Accessed: 19

Muhammad Bariq Rifqi Pasha, 2021

**EFIKASI TERAPI BONE MARROW MESENCHYMAL STEM CELLS (BM-MSCS) PADA PASIEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)**

UPN Veteran Jakarta, Fakultas Kedokteran, Program Studi Kedokteran Program Sarjana  
[[www.upnvj.ac.id](http://www.upnvj.ac.id) – [www.library.upnvj.ac.id](http://www.library.upnvj.ac.id) – [www.repository.upnvj.ac.id](http://www.repository.upnvj.ac.id)]

October 2020).

- Li, X. *et al.* (2018) 'Mesenchymal stem cells alleviate oxidative stress-induced mitochondrial dysfunction in the airways', *Journal of Allergy and Clinical Immunology*. Mosby Inc., 141(5), pp. 1634-1645.e5. doi: 10.1016/j.jaci.2017.08.017.
- Ma, S. *et al.* (2014) 'Immunobiology of mesenchymal stem cells', *Cell Death and Differentiation*. Nature Publishing Group, 21(2), pp. 216–225. doi: 10.1038/cdd.2013.158.
- MacNee, W. (2005). Pathogenesis of chronic obstructive pulmonary disease. *Proceedings of the American Thoracic Society*, 2(4), 258–266. <https://doi.org/10.1513/pats.200504-045SR>
- Mahrous, A. A., Hassanien, A. A. and Atta, M. S. (2015a) 'Predictive value of C-reactive protein in critically ill patients who develop acute lung injury', *Egyptian Journal of Chest Diseases and Tuberculosis*. Medknow, 64(1), pp. 225–236. doi: 10.1016/j.ejcdt.2014.10.006.
- Mahrous, A. A., Hassanien, A. A. and Atta, M. S. (2015b) *Predictive value of C-reactive protein in critically ill patients who develop acute lung injury - ScienceDirect, Egyptian Journal of Chest Diseases and Tuberculosis*. Available at: <https://www.sciencedirect.com/science/article/pii/S042276381420029X?via%3Dihub> (Accessed: 9 October 2020).
- Medical dictionary (2012) *Data synthesis | definition of data synthesis, The Free Dictionary by Farlex*. Available at: <https://medical-dictionary.thefreedictionary.com/data+synthesis> (Accessed: 6 October 2020).
- Mendeley - Wikipedia bahasa Indonesia, ensiklopedia bebas* (2019) *Wikipedia Ensiklopedia Bebas*. Available at: <https://id.wikipedia.org/wiki/Mendeley> (Accessed: 22 June 2020).
- Methley, A. M. *et al.* (2014a) *PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews, BMC Health Services Research*. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310146/> (Accessed: 22 June 2020).
- Methley, A. M. *et al.* (2014b) 'PICO, PICOS and SPIDER: A comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews', *BMC Health Services Research*. BioMed Central Ltd., 14(1). doi: 10.1186/s12913-014-0579-0.

**Muhammad Bariq Rifqi Pasha, 2021**

**EFIKASI TERAPI BONE MARROW MESENCHYMAL STEM CELLS (BM-MSCS) PADA PASIEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)**

UPN Veteran Jakarta, Fakultas Kedokteran, Program Studi Kedokteran Program Sarjana  
[[www.upnvj.ac.id](http://www.upnvj.ac.id) – [www.library.upnvj.ac.id](http://www.library.upnvj.ac.id) – [www.repository.upnvj.ac.id](http://www.repository.upnvj.ac.id)]

- Moher D, Liberati A, Tetzlaff J, A. D. (2009) 'PRISMA 2009 Flow Diagram', *The PRISMA GROUP*. doi: 10.1371/journal.pmed1000097.
- Moher, D. *et al.* (2015) 'Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement', *National Institute for Health Research*. doi: 10.1186/2046-4053-4-1.
- Nasution, R. E. P. (2017) *PICO: Metode Mudah Menemukan Jurnal Kedokteran*. Available at: <https://whitecoathunter.com/pico-metode-pencarian-jurnal/> (Accessed: 22 June 2020).
- Nurdan Kokturk, Fatma Yıldırım, Pınar Yıldız Gülhan, and Y. M. O. (2018) *Stem cell therapy in chronic obstructive pulmonary disease. How far is it to the clinic?*, *NCBI*. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146161/> (Accessed: 9 July 2020).
- Oh, D. K., Kim, Y. S. and Oh, Y. M. (2017a) *Lung Regeneration Therapy for Chronic Obstructive Pulmonary Disease, Tuberculosis & Respiratory Disease*. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256352/> (Accessed: 6 October 2020).
- Oh, D. K., Kim, Y. S. and Oh, Y. M. (2017b) 'Lung Regeneration Therapy For Chronic Obstructive Pulmonary Disease', *Tuberculosis and Respiratory Diseases*. Korean National Tuberculosis Association, 80(1), pp. 1–10. doi: 10.4046/trd.2017.80.1.1.
- PRISMA Flow Diagram* (2015) *PRISMA*. Available at: <http://prisma-statement.org/PRISMAStatement/FlowDiagram> (Accessed: 22 June 2020).
- Publications impact indexes - Biblioteka* (no date). Available at: <https://www.mondragon.edu/en/web/biblioteka/publications-impact-indexes> (Accessed: 1 July 2020).
- Ribeiro-Paes, J. T. *et al.* (2011a) *Unicentric study of cell therapy in chronic obstructive pulmonary disease/pulmonary emphysema*, *International Journal of Chronic Obstructive Pulmonary Disease*. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3034284/> (Accessed: 5 October 2020).
- Ribeiro-Paes, J. T. *et al.* (2011b) 'Unicentric study of cell therapy in chronic obstructive pulmonary disease/pulmonary emphysema', *International Journal of COPD*. Dove Press, 6(1), pp. 63–71. doi: 10.2147/COPD.S15292.

*Risk of bias tools - Archive: RoB 2.0 cluster-randomized trials (2016)* (2016) *Cochrane*. Available at: <https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool/archive-rob-2-0-cluster-randomized-trials-2016?authuser=0> (Accessed: 20 October 2020).

S Ma, N Xie, W Li, B Yuan, Y. S. & Y. W. (2013) *Immunobiology of mesenchymal stem cells, Cell Death & Differentiation*. Available at: <https://www.nature.com/articles/cdd2013158> (Accessed: 9 July 2020).

Shihua Wang, X. Q. & R. C. Z. (2012) *Clinical applications of mesenchymal stem cells*, *SpringerLink*. Available at: <https://link.springer.com/article/10.1186/1756-8722-5-19> (Accessed: 9 July 2020).

Siswanto (2017) *Systematic Review Sebagai Metode Penelitian Untuk Mensintesis Hasil-Hasil Penelitian (Sebuah Pengantar)*.

Soeroto, arto. (n.d.). *UPDATE KNOWLEDGE IN RESPIROLOGY*.

Stessuk, T. *et al.* (2013a) *Phase I clinical trial of cell therapy in patients with advanced chronic obstructive pulmonary disease: follow-up of up to 3 years*, *Revista Brasileira De Hematologia E Hemotrapia*. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832317/> (Accessed: 5 October 2020).

Stessuk, T. *et al.* (2013b) ‘Phase I clinical trial of cell therapy in patients with advanced chronic obstructive pulmonary disease: Follow-up of up to 3 years’, *Revista Brasileira de Hematologia e Hemoterapia*. Sociedade Brasileira de Hematologia e Hemoterapia, 35(5), pp. 352–357. doi: 10.5581/1516-8484.20130113.

Stolk, J. *et al.* (2016a) *A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema*, *QJM: An International Journal of Medicine*. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888332/> (Accessed: 5 October 2020).

Stolk, J. *et al.* (2016b) ‘A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema’, *QJM: An International Journal of Medicine*. Oxford University Press, 109(5), pp. 331–336. doi: 10.1093/qjmed/hcw001.

Sun, Z. *et al.* (2018a) ‘Stem cell therapies for chronic obstructive pulmonary disease: Current status of pre-clinical studies and clinical trials’, *Journal of Thoracic Disease*. AME Publishing Company, 10(2), pp. 1084–1098. doi:

10.21037/jtd.2018.01.46.

Sun, Z. *et al.* (2018b) *Stem cell therapies for chronic obstructive pulmonary disease: current status of pre-clinical studies and clinical trials - Sun - Journal of Thoracic Disease, Journal of Thoracic Disease.* Available at: <http://jtd.amegroups.com/article/view/18654/15050> (Accessed: 5 October 2020).

*Systematic Reviews : Data Extraction* (2019) *Stony Brook University.* Available at: <https://guides.library.stonybrook.edu/c.php?g=226681&p=3624445> (Accessed: 22 June 2020).

Terence Ho, Ruth P. Cusack, Nagendra Chaudhary, Imran Satia, and O. P. K. (2019) *Under- and over-diagnosis of COPD: a global perspective, National Institute for Health Research.* Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395975/> (Accessed: 9 July 2020).

Wang, S., Qu, X. and Zhao, R. C. (2012) ‘Clinical applications of mesenchymal stem cells’, *Journal of Hematology and Oncology.* BioMed Central, 5(1), pp. 1–9. doi: 10.1186/1756-8722-5-19.

Weiss, D. J. *et al.* (2013a) ‘A placebo-controlled, randomized trial of mesenchymal stem cells in COPD’, *Chest.* American College of Chest Physicians, 143(6), pp. 1590–1598. doi: 10.1378/chest.12-2094.

Weiss, D. J. *et al.* (2013b) *A Placebo-Controlled, Randomized Trial of Mesenchymal Stem Cells in COPD, CHEST.* Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694112/> (Accessed: 5 October 2020).

*What are systematic reviews?* (2020) *Cochrane.* Available at: <https://www.cochrane.org/news/what-are-systematic-reviews> (Accessed: 22 June 2020).

Xiang Li, P. \* *et al.* (2018) *Mesenchymal stem cells alleviate oxidative stress–induced mitochondrial dysfunction in the airways, The Journal of Allergy and Clinical Immunology.* Available at: [https://www.jacionline.org/article/S0091-6749\(17\)31431-8/fulltext](https://www.jacionline.org/article/S0091-6749(17)31431-8/fulltext) (Accessed: 9 July 2020).